These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29473382)

  • 21. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder.
    Wang J; Zhou Z; Cui Y; Li Y; Yuan H; Gao Z; Zhu Z; Wu J
    Neurourol Urodyn; 2019 Jan; 38(1):22-30. PubMed ID: 30350884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessing Preference-Based Outcome Measures for Overactive Bladder: An Evaluation of Patient-Reported Outcome Data from the BESIDE Clinical Trial.
    Herdman M; Nazir J; Hakimi Z; Siddiqui E; Huang M; Pavesi M; MacDiarmid S; Drake MJ; Devlin N
    Patient; 2017 Dec; 10(6):677-686. PubMed ID: 28646416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Severity of overactive bladder symptoms and response to dose escalation in a randomized, double-blind trial of solifenacin (SUNRISE).
    Cardozo L; Amarenco G; Pushkar D; Mikulas J; Drogendijk T; Wright M; Compion G;
    BJU Int; 2013 May; 111(5):804-10. PubMed ID: 23294801
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of combined solifenacin and aclatonium in preventing dry mouth in patients with overactive bladder.
    Park HK; Kim HG; Yang DY; Choi WS; Paick SH; Chung H; Yang SK
    Low Urin Tract Symptoms; 2019 Jan; 11(1):56-60. PubMed ID: 28967201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tamsulosin plus a new complementary and alternative medicine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Results from a retrospective comparative study.
    Fusco F; Creta M; Trama F; Esposito F; Crocetto F; Aveta A; Mangiapia F; Imbimbo C; Capece M; La Rocca R; Mirone V; Longo N
    Arch Ital Urol Androl; 2020 Oct; 92(3):. PubMed ID: 33016038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
    Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
    Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Efficacy and Safety of OnabotulinumtoxinA or Solifenacin Compared with Placebo in Solifenacin Naïve Patients with Refractory Overactive Bladder: Results from a Multicenter, Randomized, Double-Blind Phase 3b Trial.
    Herschorn S; Kohan A; Aliotta P; McCammon K; Sriram R; Abrams S; Lam W; Everaert K
    J Urol; 2017 Jul; 198(1):167-175. PubMed ID: 28161352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mirabegron Versus Solifenacin in Multiple Sclerosis Patients With Overactive Bladder Symptoms: A Prospective Comparative Nonrandomized Study.
    Brucker BM; Jericevic D; Rude T; Enemchukwu E; Pape D; Rosenblum N; Charlson ER; Zhovtis-Ryerson L; Howard J; Krupp L; Peyronnet B
    Urology; 2020 Nov; 145():94-99. PubMed ID: 32822687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of efficacy and tolerability of pharmacological treatment for the overactive bladder in women: A network meta-analysis.
    Nalliah S; Wg P; Masten Singh PK; Naidu P; Lim V; Ahamed AA
    Aust Fam Physician; 2017 Mar; 46(3):139-144. PubMed ID: 28260277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy: Responder Analyses and Patient-Reported Outcomes from the BESIDE Study [corrected].
    MacDiarmid S; Al-Shukri S; Barkin J; Fianu-Jonasson A; Grise P; Herschorn S; Saleem T; Huang M; Siddiqui E; Stölzel M; Hemsted C; Nazir J; Hakimi Z; Drake MJ;
    J Urol; 2016 Sep; 196(3):809-18. PubMed ID: 27063854
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Therapeutic Efficacy and Urodynamic Findings of Solifenacin Succinate versus Mirabegron in Women with Overactive Bladder Syndrome: Results of a Randomized Controlled Study.
    Vecchioli Scaldazza C; Morosetti C
    Urol Int; 2016; 97(3):325-329. PubMed ID: 27092789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A proof-of-concept study: mirabegron, a new therapy for overactive bladder.
    Chapple CR; Amarenco G; López Aramburu MA; Everaert K; Liehne J; Lucas M; Vik V; Ridder A; Snijder R; Yamaguchi O;
    Neurourol Urodyn; 2013 Nov; 32(8):1116-22. PubMed ID: 23424164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study.
    Robinson D; Oelke M; Khullar V; Wijkstra H; Tretter R; Stow B; Compion G; Tubaro A
    Neurourol Urodyn; 2016 Sep; 35(7):819-25. PubMed ID: 26199198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of imidafenacin for overactive bladder in adult: a systematic review and meta-analysis.
    Huang W; Zong H; Zhou X; Zhang Y
    Int Urol Nephrol; 2015 Mar; 47(3):457-64. PubMed ID: 25636812
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and tolerability of solifenacin in men with overactive bladder: results of an observational study.
    Burger M; Betz D; Hampel C; Vogel M
    World J Urol; 2014 Aug; 32(4):1041-7. PubMed ID: 24135915
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Persistence of solifenacin therapy in patients with overactive bladder in the clinical setting: a prospective, multicenter, observational study.
    Kim TH; You HW; Park JH; Lee JG; Choo MS; Park WH; Lee JZ; Park CH; Na YG; Kwon DD; Lee KS
    Int J Clin Pract; 2016 Apr; 70(4):351-7. PubMed ID: 27028673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.